EP300 as one of frequently mutated genes in the bladder cancer was significantly associated with increased TMB and enhanced antitumor immune response, which might serve as a new biomarker to predict clinical prognosis and immune response in bladder cancer [42]. This evidence concerns the gene EP300 and urinary bladder cancer.